核芯针活检在乳腺癌新辅助化疗前的组织学诊断评价  

Diagnostic value of core needle biopsy before neoadjuvant chemotherapy for breast cancer

作　　者：郑闪[1] 张柏林[2] 邹霜梅[1] 林冬梅[1] 薛丽燕[1] 罗巍[1] 吕宁[1] 

机构地区：[1]中国医学科学院北京协和医学院肿瘤医院肿瘤研究所病理科,100021 [2]中国医学科学院北京协和医学院肿瘤医院肿瘤研究所外科,100021

出　　处：《中华病理学杂志》2008年第2期99-102,共4页Chinese Journal of Pathology

基　　金：北京市科技计划课题项目基金资助（D0905001040131）

摘　　要：目的评价核芯针活检（CNB）作为乳腺癌新辅助化疗前组织病理学诊断依据的价值。方法收集2005年6月至2007年1月本院入组新辅助化疗患者119例，化疗前以CNB作为组织学诊断依据；化疗后乳腺改良根治标本按Miller和Payne分级系统标准取材；每例化疗前后病理切片均由两名主检医师双盲法独立诊断，并比较其诊断的符合率。结果CNB诊断为癌110例，其中浸润性癌105例，导管内癌5例。治疗前后浸润性癌的诊断符合率为97．2％（105／108）。结论CNB在乳腺癌新辅助化疗术前对于明确病变的良恶性具有诊断优势，对鉴别肿瘤组织是否为浸润性癌具有重要参考价值。Objective To assess the diagnostic value of core needle biopsy （CNB） before neoadjuvant chemotherapy for breast cancer. Methods One hundred and nineteen breast cancer cases underwent neoadjuvant chemotherapy in our hospital during the period from June, 2005 to January, 2007 were analyzed. CNB was carried out before starting chemotherapy. The hematoxylin and eosin-stained slides of CNB taken before and after neoadjuvant chemotherapy were reviewed independently by two pathologists, and the rate of consistency was verified. Results Amongst the 119 cases studied, 110 cases were confirmed to be carcinoma, including 105 cases of invasive carcinoma and 5 cases of ductal carcinoma-in-situ. The rate of consistency was 97.22% （105/108）. Conclusion CNB has important value in distinguishing benign from malignant lesions, as well as in confirming the diagnosis of invasive carcinoma before starting neoadjuvant chemotherapy.

关 键 词：乳腺肿瘤 活组织检查 针吸 诊断 化学疗法 辅助 

分 类 号：R686[医药卫生—骨科学]